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Background: The purpose of this study was to elucidate the effects of glimepiride on the levels of biomarkers
related to cardiovascular regulation in patients with type 2 diabetes mellitus.
Methods and results: Thirty-four patients with type 2 diabetes received glimepiride for 24 weeks. Significant
decreases in the levels of glyceraldehyde-derived advanced glycation end products, (glycer-AGE: toxic AGE), eotaxin
and fibroblast growth factor (FGF)-2 were recognized after the administration of glimepiride. Moreover, there were
trends for there to be increases in the levels of granulocyte-colony stimulating factor (G-CSF) and granulocyte
macrophage-colony stimulating factor (GM-CSF), and decreases in the levels of fractalkine, soluble CD40 ligand
(sCD40L), macrophage inflammatory protein (MIP)-β, vascular endothelial growth factor (VEGF) and soluble receptor
for AGE (sRAGE).
Conclusions: Glimepiride may have potent anti-oxidative, anti-inflammatory and angiogenic properties and it may
potentially repair tissue damage by decreasing the levels of toxic AGE and increasing colony-stimulating factors.
Keywords: Glimepiride, Advanced glycation end products, Cytokines/chemokines, Growth factors,
Diabetes mellitus type 2Introduction
Diabetes mellitus continues to increase in terms of the
number of affected and in significance worldwide, and is a
growing burden with regard to public health. It is estimated
that there were 285 million people worldwide with diabetes
in 2010, and this number is expected to increase 439 million
by 2030 [1]. Type 2 diabetes is a metabolic disorder charac-
terized by chronic hyperglycemia resulting from a progres-
sive insulin secretory defect on the background of insulin
resistance, usually leading to absolute insulin deficiency,
which results in complex phenomena exacerbated by central
obesity [2], and increases the risk for atherosclerosis and re-
lated cardiovascular disease [3-6]. Therefore, optimal anti-
diabetic treatment requires beneficial effects that can help to* Correspondence: junoyama@cc.saga-u.ac.jp
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stated.prevent diabetic complications, in addition to providing
good glycemic control.
Glimepiride is a second-generation sulfonylurea that
stimulates pancreatic β cells to release insulin. This agent
mainly stimulates insulin secretion, but has also been
shown to have additional extra-pancreatic effects in animal
models [7,8]. The aim of this study was to elucidate the
beneficial effects of glimepiride on cardiovascular system-
related biomarkers in diabetic patients.Methods
Subjects
Forty-five patients who agreed to participate in this study
were enrolled. The entry criteria included 1) age > 30 years
old, 2) type 2 diabetes with a hemoglobin A1c (HbA1c)
value > 6.5% and 3) under treatment with diet, exercise,
alpha glucosidase inhibitors (α-GIs), and/or first generation
sulfonylurea drugs, such as glibenclamide (< 5 mg/day) or
gliclazide (< 80 mg). The exclusion criteria were 1) severeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Participant flow.
Table 1 Baseline characteristics of the patients
n (%)
Gender Male 24 (70.6%)
Female 10 (29.4%)
Age (y.o.) 64.7 ± 1.4
Height (cm) 160.6 ± 1.5
Body weight (kg) 66.5 ± 1.9






CAD or CVD 11 (32.4%)
Drug(s) ACEI/ARB 21 (61.8%)
Ca antagonist 24 (70.6%)
Diuretics 9 (26.5%)
HMG-CoA reductase 22 (64.7%)
BMI: body mass index, CAD: coronary artery disease, CVD: cerebrovascular
disease, ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin 2
receptor blocker, HMG-CoA reductase: hydroxymethylglutaryl-CoA reductase.
Nakamura et al. Cardiovascular Diabetology 2014, 13:15 Page 2 of 8
http://www.cardiab.com/content/13/1/15diabetic complications such as > stage 3A nephropathy or >
stage B retinopathy, 2) liver dysfunction, as indicated by an
AST > 80 IU/l or ALT > 80 IU/l, 3) cancer, 4) renal dysfunc-
tion (serum creatinine > 2.0 mg/dl) and 5) receiving the
treatment with oral glimepiride, metformin or pioglitazone.
The study protocol was approved by the Institutional
Review Committee on Human Research at Saga University
and by other institutions. Informed consent was obtained
from each patient.
Study protocol
All patients received treatment with glimepiride after study
entry. Glimepiride was started as: 1) a new medication in
diabetic patients receiving diet/exercise therapy but no
anti-diabetic agents; 2) additional therapy in combination
with α-GIs in patients with poorly controlled glucose; or
3) in exchange for first generation sulfonylurea agents,
such as glibenclamide or gliclazide in patients with
poorly controlled glucose. The dose of glimepiride was
started at 1 mg daily and increased up to 6 mg daily until a
value of HbA1c < 6.5% was achieved in patients who re-
ceived glimepiride as a new medication or an additional
therapy to α-GIs. If the glimepiride was given in place of
glibenclamide or gliclazide, the starting dose of glimepiride
was decided by referring to previous reports indicating
that 1 mg of glimepiride corresponded to 1.5 mg of
glibenclamide or 20 mg of gliclazide. Adverse events were
recorded continuously. In all of the entry patients, various
blood biomarkers related to cardiovascular pathophysi-
ology were measured at baseline before starting glimepiride
treatment and 24 weeks after the start of glimepiride
treatment.
Measurement of advanced glycation end products
The concentrations of glyceraldehyde-derived advanced
glycation end products (glycer-AGE), one of the toxic AGE
present in the serum, were measured with a competitive
ELISA using an immunopurified glycer-AGE antibody [9].
In brief, 96-well microtiter plates were coated with 1 μg/ml
glycer-AGE-bovine serum albumin (BSA) per well, and
were kept overnight in a cold room. The wells were
washed three times with 0.3 ml of phosphate-buffered saline
(PBS)-Tween-20. Wells were then blocked by incubation for
1 h with 0.2 ml of PBS containing 1% BSA. After washing
with PBS-Tween-20, test samples (50 μl) were added to
each well as a competitor for 50 μl of the glycer-AGE
antibody (1:1000), followed by incubation for 2 h at room
temperature with gentle shaking by a horizontal rotary
shaker. The wells were then washed with PBS-Tween-20
and developed with an alkaline-phosphatase-linked anti-
rabbit IgG utilizing p-nitrophenyl phosphate as a colori-
metric substrate. The results are expressed as glycer-AGE
units (U) per milliliter of serum, with 1 U corresponding
to 1 μg of glycer-AGE-BSA standard. The sensitivity andintra- and inter-assay coefficients of variation were 0.01
U/ml, 6.2 and 8.8%, respectively. The level of the soluble
form of the receptor for AGE (sRAGE) was measured
using an ELISA kit (R & D Systems Inc, Minneapolis,
MN, USA), as described previously [10].
Other measurements
The following parameters were assessed at baseline before
starting glimepiride treatment and 24 weeks after starting
the glimepiride treatment. The fasting plasma levels of glu-
cose and insulin and the hemoglobin A1c (HbA1c) were
measured, and the insulin resistance was determined using
Matthews’s homeostasis model assessment (HOMA). The
HOMA-β and HOMA-R were based on the following for-
mula: 360 × fasting plasma insulin (μU/mL)/[fasting blood
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fasting plasma insulin (μU/mL)/405, respectively. We
measured the brain natriuretic peptide (BNP) level using a
chemiluminescent enzyme immunoassay method. High-
sensitivity C-reactive protein (hsCRP) was measured by
particle-enhanced immunonephelometric assays. High
molecular weight (HMW) adiponectin was measured
using a sandwich ELISA kit (Fujirebio, Tokyo, Japan)
based on detection by a monoclonal antibody against
human HMW adiponectin, IH7 [11]. The plasma PTX3
levels were measured with a sandwich ELISA based on a
previously described method [12]. Then, we performed a
fluorescent microbead-based assay to measure multipleFigure 2 The changes in the levels of fasting plasma glucose (a), HbA
(e) after the treatment with glimepiride. *p < 0.05, **p < 0.01 versus befo
model assessment.cytokines and chemokines using a Luminex 100 instrument
(Luminex Corp, Austin, TX) with a MILLIPLEX MAP
Human Cytokine/Chemokine kit (Millipore, Billerica,
MA), as described previously [13], to determine the levels
of various cytokines, chemokines and growth factors, in-
cluding interleukin (IL)-1β, IL-6, tumor necrosis factor
(TNF)-α, monocyte chemoattractant protein (MCP)-1,
interferon (IF)-γ, granulocyte-colony stimulating factor
(G-CSF), granulocyte macrophage-colony stimulating
factor (GM-CSF), eotaxin, fibroblast growth factor (FGF)-2,
vascular endothelial growth factor (VEGF), soluble
CD40 ligand, fractalkine and macrophage inflammatory
protein (MIP)-β.1c (b), fasting plasma insulin (c), HOMA-R (d) and HOMA-β
re treatment. HbA1c = hemoglobin A1c, HOMA = homeostasis
Table 2 The effects of the changes in biochemical
markers on DM patients
Before administration 24 weeks
after treatment
p
BNP 39.2 ± 10.8 33.6 ± 10.4* 0.048
hsCRP 1859.5 ±426.7 2600.2 ± 745.9 0.254
HMW adiponectin 3.58 ± 0.43 3.82 ±0.53 0.468
PTX3 2.39 ± 0.26 2.16 ±0.29 0.082
IL-1β 2.23 ± 7.66 2.57 ±8.91 0.297
IL-6 3.62 ± 8.90 3.69 ±9.18 0.879
TNF-α 4.34 ±2.00 4.38 ± 1.17 0.872
MCP-1 554.78 ±204.55 565.88 ± 211.85 0.581
IFN-γ 3.94 ± 5.52 3.97 ± 4.75 0.9419
BNP: brain natriuretic peptide, hs CRP: high-sensitive C-reactive protein, HMW:
high molecular weight, PTX3 pentraxin-3, IL: interleukin, MCP-1: monocyte
chemoattractant protein-1, IFN: interferon.
*p<0.05 vs before treatment.
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The data were expressed as the means ± SEM unless other-
wise indicated. The statistical significance of differences
between groups were analyzed by Student’s t-test or the
Wilcoxon signed-ranks test using the SPSS software
program, and values of p < 0.05 were considered to be
significant.
Results
Baseline characteristics of the patients
Of the 45 patients enrolled in this study, six (13%) were
taking glibenclamide, one (2%) was taking gliclazide and
fourteen (31%) were taking α-GI at the time of entry. All
45 patients were taking antihypertensive medications,
such as angiotensin-converting converting enzyme inhibi-
tors (ACEI) and/or angiotensin II receptor blockers (ARB)
(27 patients, 60%), β-blockers (15 patients, 33%) or cal-
cium channel antagonists (30 patients, 67%). Nine (20%)
patients were taking diuretics and 26 (57%) patients were
taking hydroxymethylglutaryl-CoA (HMG-CoA) reductase
inhibitors. The patients had histories of the following
cardiovascular diseases: old myocardial infarction in 10
(22%), angina pectoris in seven (16%), old cerebral in-
farction in three (7%), heart failure in three (7%), ab-
dominal aortic aneurysm in two (4%), paroxysmal atrial
fibrillation in two (4%), transient ischemic attack in one
(2%) and an aortic dissection in one (%) patient.
Of the 45 enrolled patients, 11 patients were excluded
from the analysis because of failed follow-up in 10 patients
(3 patients: withdrawn, 7 patients: moved) and unstable
angina pectoris in one patient, and thus, a total of 34
patients completed the study protocol (Figure 1). The clinical
profiles of the 34 evaluated patients are shown in Table 1.
Glycemic control
Figure 2.
The levels of HbA1c and fasting plasma glucose (FPG)
decreased, and the HOMA-β value increased signifi-
cantly following the start of glimepiride. However, the
plasma insulin level and HOMA-R value were compar-
able before and after the treatment (Figure 1). After 24
weeks, 23 patients achieved a HbA1c < 6.5%. At 24
weeks, the mean dose of glimepiride was 2.6 mg, and 13
patients (38%) who received treatment with only 1 mg of
glimepiride achieved a HbA1c < 6.5%. Six patients (17%)
had mild hypoglycemia who had symptoms but recov-
ered without intensive assistance and no patient had
severe hypoglycemia who required a third party to
intervene actively during the study.
Assessment of biomarker changes after the
administration of glimepiride
The levels of hsCRP, PTX3 and most of the inflammatory
cytokines, including IL-1β, IL-6, TNF-α, IFN−γ and MCP-1, did not change after glimepiride treatment, while the
BNP level significantly decreased (Table 2). The levels of
eotaxin (p = 0.0347), FGF-2 (p = 0.0429) and toxic AGE
(p = 0.0452) decreased significantly after the treatment.
Moreover, a trend toward an increase in the levels of G-CSF
(p = 0.1725) and GM-CSF (p = 0.0525), and a decrease in
the levels of VEGF (p = 0.0519), soluble CD40 ligand
(p = 0.1923), fractalkine (p = 0.0542), MIP-β (p = 0.1126) and
soluble RAGE (p = 0.1655) were observed (Figure 3).
Discussion
In this study, we found that glimepiride significantly
suppressed the plasma levels of eotaxin, FGF-2 and toxic
AGE, and showed a trend to reduce those of fractalkine,
sCD40L, MIP-β, VEGF and sRAGE, and to increase the
levels of G-CSF and GM-CSF.
Sulfonylureas may increase the risk of cardiovascular
events in patients with type 2 diabetes [14]. However,
glimepiride seems to have fewer unfavorable cardiovascu-
lar effects compared to other sulfonylureas. Glimepiride
upregulated eNOS activity and inhibit NF-kB activation in
human umbilical vein endothelial cells [15]. In open-chest
dogs, intracoronary infusion of glibenclamide, gliclazide
and glimepiride all reduced coronary blood flow, increased
coronary resistance, depressed the mechanical activity of
the heart, enhanced myocardial O2-extraction, reduced
the serum potassium level and induced a moderate
endocardial ST-segment elevation, but glimepiride to a
significantly less extent than glibenclamide and gliclazide
[16]. Likely underlying the favorable cardiovascular effects
of glimepiride are its induction of ischemic precondition-
ing, suppression of ventricular tachycardia and lowering
of the blood pressure, unlike other sulfonylureas [17-19].
Unfortunately, these effects has previously been shown
only in animal experiments. Therefore, in this study, we
provided the first demonstration of the clinical effects of
Figure 3 (See legend on next page.)
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Figure 3 The changes in the serum or plasma levels of G-CSF (a), GM-CSF (b), eotaxin (c), FGF-2 (d), VEGF (e), soluble CD40 ligand (f),
fractalkine (g), MIP-β (h), glycer-AGEs (i) and sRAGE (j) by the treatment with glimepiride. Open bars indicate “before treatment” and solid
bars indicate “after treatment”. *p < 0.05 versus before treatment. G-CSF = granulocyte colony-stimulating factor, GM-CSF = granulocyte
macrophage-colony stimulating factor, FGF = fibroblast growth factor, VEGF = vascular endothelial growth factor, MIP = macrophage inflammatory
protein, glycer-AGE = glyceraldehyde-derived advanced glycation end products, sRAGE = soluble receptor for advanced glycation end products.
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glimepiride and rosiglitazon reduced the levels of hsCRP,
AGEs [20], lipoprotein, homocyctein and plasminogen ac-
tivator inhibitor-1 [21] increased adiponectin [22] in
T2DM. Recently phase 3 trial of empagliflozin, SGLT2
inhibitor, versus glimepiride as add-on to metformin in
T2DM patients are being performed [23]. However, the
study about exenatide, GLP-1 agonist, versus glimepiride
added to metformin revealed that glimepiride reduced
hsCRP and increased adiponectin although exenatide
did with great extent [24]. Moreover, glimepiride could
not prevent the atherosclerosis of carotid intima-media
thickness [25] and coronary atherosclerosis [26] compared
with pioglitazone.
AGEs are oxidative products formed from the reaction
between carbohydrates and a free amino group of pro-
teins, which are provoked by reactive species and are
greatly accelerated in response to the hyperglycemia and
oxidative stress that occur in diabetic subjects [27].
Since the AGEs activate nuclear factor-κB (NF-κΒ) and
activator protein-1 (AP-1), transcription factors, which
upregulates the expression of genes involved in vascular
injury and endothelial dysfunction, in microvascular
endothelial cells and induce angiogenesis, lowing the
AGEs may contribute to ameliorating diabetic vascu-
lopathy [20,28-30]. The serum levels of toxic AGE were
inversely associated with the number of endothelial
progenitor cells in apparently healthy subjects [31]. The
reduction in toxic AGE and sRAGE by glimepiride in
our present study, therefore, the results may suggest that
glimepiride have a potential benefit for repairing the vas-
cular injury and stop angiogenesis in diabetic patients.
In this study, there was a trend toward an increase in
the level of G-CSF and GM-CSF after the administration
of glimepiride for 24 weeks, suggesting that glimepiride
has effects on angiogenesis, which is a pivotal mechan-
ism that influences several physiological and pathological
processes, including wound healing, because GM-CSF is
known to induce bone marrow precursors to protect
against the development of diabetes and to induce
wound healing in diabetic mice [32-34]. In our study,
the plasma levels of FGF-2 and VEGF were also reduced
after the administration of glimepiride. FGF-2 is a potent
mitogen in endothelial cells and smooth muscle cells that
is released after endothelial injury [35] and is capable of
inducing smooth muscle cell migration and proliferation,
leading to neointima formation [36,37]. The plasma FGF-2level is low or undetectable in healthy subjects [38], but in-
creases in microalbuminuric adult type 2 diabetic patients.
Both FGF-2 and VEGF are considered to be key factors
in the angiogenic response [39,40], and induce increased
vascular permeability. The vascular hyperpermeability and
increased blood flow caused by elevated tissue glucose
and sorbitol levels can be blocked by neutralizing mono-
clonal and polyclonal antibodies directed against VEGF
[41], suggesting that a sorbitol pathway-linked increase in
VEGF may be involved in the hemodynamic changes
and loss of endothelial cell barrier integrity induced by
diabetes. Increased glucose induces the production of
VEGF and FGF-2 to promote angiogenesis, and to protect
against tissue injury. In our study, however, glimepiride re-
duced the plasma levels of VEGF and FGF-2.
We believe that the results of treatment may depend on
the decreased induction of cytokines resulting from the
glycemic improvement or via the pleiotropic effects of the
drug. It was previously reported that patients with type
1 diabetes showed higher concentrations of plasma
GM-CSF, soluble CD40, soluble CD40 ligand, MIP-β [42],
and that the acute effect of clamped hyperglycemia in-
creased the urinary excretion of eotaxin, FGF-2, GM-CSF,
TNF-α and soluble CD40 ligand in patients with type 1
diabetes. Based on these results, our data supplements the
favorable cardiovascular effects of glimepiride, which is
in contrast to the unfavorable cardiac effects of other
sulfonylureas.
In our study, the level of eotaxin also decreased after
glimepiride treatment. Eotaxin is a potent eosinophil
chemoattractant that is a member of the CC chemokine
subfamily of inflammatory and immunoregulatory cyto-
kines. Although the role of eotaxin in diabetes is still be-
ing elucidates, it is thought to be substantially involved
in the development of the disease in patients with type 1
diabetes [43]. Moreover, in patients with type 2 diabetes, in-
sulin infusion reduced the levels of eotaxin and MCP-1 [44],
and the eosinophil count is also related to albumin excretion
in males [45]. Although the role of eotaxin in diabetes is still
unclear, the protein sequence of human eotaxin is 66% iden-
tical to that of human MCP-1. Therefore, the decrease in
eotaxin by glimepiride may reflect its potent anti-diabetic
properties.
Limitations
This was a preliminary single-arm study that was designed
to evaluate only six months of treatment in a small number
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drug and it is hard to avoid the use of glimepiride in the
control group for 6 months in real clinical world when
randomized placebo-control group is performed. Therefore,
we performed a single-arm study as preliminary report.
In this study, we confirmed that glimepiride may have
angiogenic properties. However, we did not evaluate
the effects of the treatment on diabetic retinopathy be-
cause there were no patients with diabetic retinopathy
in our group. Therefore, future studies will be needed
to determine whether glimepiride can ameliorate or
prevent diabetic complications including macro- and
microagiopathies.
We also did not elucidate whether these phenomenona
depended specifically on the glycemic control or were
affected by other feature of glimepiride. However, we
confirmed that these results did not correlate with the low-
ering of the blood glucose level or the level of HbA1c.
Therefore, these results may depend on the unique features
of the drug itself.
Conclusions
In conclusion, the present study demonstrated that
glimepiride may have beneficial effects beyond improving
the glycemic control by reducing the toxic AGE and indu-
cing CSFs.
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